Aktienanalyse zu BioLife Solutions, Inc. (BLFS)BLFSBioLife Solutions, Inc.

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

BioLife Solutions is currently not a strong buy. The stock is trading at $36.38, which is above the analyst price target of $31, indicating limited upside potential. Additionally, the recent insider selling has increased by 3374.62%, suggesting a lack of confidence from insiders. While the company has shown a remarkable year-to-date change of +52.28%, the forward P/E ratio of 322.58 indicates that the stock may be overvalued at this price level.

3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.